• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早期和晚期结直肠癌患者肝切除术后 RAS 对总生存预后的影响。

The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients.

机构信息

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Br J Cancer. 2021 Feb;124(4):797-804. doi: 10.1038/s41416-020-01169-w. Epub 2020 Nov 19.

DOI:10.1038/s41416-020-01169-w
PMID:33208919
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7884678/
Abstract

BACKGROUND

The impact of molecular aberrations on survival after resection of colorectal liver metastases (CLM) in patients with early-age-onset (EOCRC) versus late-age-onset colorectal cancer (LOCRC) is unknown.

METHODS

Patients who underwent liver resection for CLM with known RAS, BRAF and MSI status were retrospectively studied. The prognostic impact of RAS mutations by age was analysed with age as a categorical variable and a continuous variable.

RESULTS

The study included 573 patients, 192 with EOCRC and 381 with LOCRC. The younger the age of onset of CRC, the greater the negative impact on overall survival of RAS mutations in the LOCRC, EOCRC, and ≤40 years (hazard ratio (HR), 1.64 (95% confidence interval (CI), 1.23-2.20), 2.03 (95% CI, 1.30-3.17), and 2.97 (95% CI, 1.44-6.14), respectively. Age-specific mortality risk and linear regression analysis also demonstrated that RAS mutations had a greater impact on survival in EOCRC than in LOCRC (slope: -4.07, 95% CI -8.10 to 0.04, P = 0.047, R = 0.08).

CONCLUSION

Among patients undergoing CLM resection, RAS mutations have a greater negative influence on survival in patients with EOCRC, more so in patients ≤40 years, than in patients with LOCRC and should be considered as a prognostic factor in multidisciplinary treatment planning.

摘要

背景

在早发性结直肠癌(EOCRC)与晚发性结直肠癌(LOCRC)患者中,结直肠肝转移(CLM)切除术后分子异常对生存的影响尚不清楚。

方法

本研究回顾性分析了已知 RAS、BRAF 和 MSI 状态的 CLM 患者行肝切除术的病例。以年龄为分类变量和连续变量分析 RAS 突变对年龄的预后影响。

结果

本研究共纳入 573 例患者,其中 192 例为 EOCRC,381 例为 LOCRC。CRC 的发病年龄越小,LOCRC、EOCRC 和≤40 岁患者中 RAS 突变对总生存的负面影响越大(风险比(HR)分别为 1.64(95%置信区间(CI),1.23-2.20)、2.03(95% CI,1.30-3.17)和 2.97(95% CI,1.44-6.14))。年龄特异性死亡率风险和线性回归分析也表明,RAS 突变对 EOCRC 患者的生存影响大于 LOCRC(斜率:-4.07,95% CI-8.10 至 0.04,P=0.047,R=0.08)。

结论

在接受 CLM 切除术的患者中,RAS 突变对 EOCRC 患者的生存有更大的负面影响,在≤40 岁的患者中比 LOCRC 患者更为显著,应在多学科治疗计划中作为预后因素考虑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83c9/7884678/3e6f31467800/41416_2020_1169_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83c9/7884678/0b88c4afe605/41416_2020_1169_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83c9/7884678/3e6f31467800/41416_2020_1169_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83c9/7884678/0b88c4afe605/41416_2020_1169_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83c9/7884678/3e6f31467800/41416_2020_1169_Fig2_HTML.jpg

相似文献

1
The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients.早期和晚期结直肠癌患者肝切除术后 RAS 对总生存预后的影响。
Br J Cancer. 2021 Feb;124(4):797-804. doi: 10.1038/s41416-020-01169-w. Epub 2020 Nov 19.
2
RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.RAS 基因突变状态可预测行肝切除术的结直肠癌肝转移患者的生存和复发模式。
Ann Surg. 2013 Oct;258(4):619-26; discussion 626-7. doi: 10.1097/SLA.0b013e3182a5025a.
3
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.KRAS和BRAF突变会限制转移性结直肠癌患者肝切除的获益吗?一项系统评价和荟萃分析。
Crit Rev Oncol Hematol. 2016 Mar;99:150-7. doi: 10.1016/j.critrevonc.2015.12.015. Epub 2016 Jan 2.
4
Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.KRAS 或 BRAF 突变型结直肠癌肝转移且微卫星不稳定状态阴性患者的预后较差。
J Hepatobiliary Pancreat Sci. 2013 Feb;20(2):223-33. doi: 10.1007/s00534-012-0531-9.
5
Genomic and prognostic heterogeneity among RAS/BRAF /TP53 co-mutated resectable colorectal liver metastases.可切除结直肠癌肝转移中 RAS/BRAF/TP53 共突变的基因组和预后异质性。
Mol Oncol. 2021 Apr;15(4):830-845. doi: 10.1002/1878-0261.12885. Epub 2021 Jan 8.
6
Molecular characteristics of early-onset compared with late-onset colorectal cancer: a case controlled study.早发性与晚发性结直肠癌的分子特征比较:一项病例对照研究。
Int J Surg. 2024 Aug 1;110(8):4559-4570. doi: 10.1097/JS9.0000000000001584.
7
Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.术前二线化疗后结直肠癌肝转移灶切除术后的预后因素:RAS 突变的影响
Eur J Surg Oncol. 2016 Sep;42(9):1378-84. doi: 10.1016/j.ejso.2016.02.249. Epub 2016 Mar 5.
8
Mutation Status of , and is Superior to Mutation Status of Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases.对于结直肠癌肝转移切除术后的预后, 突变状态优于 突变状态。
Clin Cancer Res. 2019 Oct 1;25(19):5843-5851. doi: 10.1158/1078-0432.CCR-19-0863. Epub 2019 Jun 20.
9
RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases.RAS突变可预测接受结直肠癌肝转移灶切除患者的切缘阳性及切缘较窄情况。
Ann Surg Oncol. 2016 Aug;23(8):2635-43. doi: 10.1245/s10434-016-5187-2. Epub 2016 Mar 25.
10
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.BRAF和RAS突变作为接受肝切除的转移性结直肠癌患者的预后因素
Br J Cancer. 2015 Jun 9;112(12):1921-8. doi: 10.1038/bjc.2015.142. Epub 2015 May 5.

引用本文的文献

1
Associations with other cancer-related biomarkers might contribute to poor outcomes in RAS-altered, younger patients with colorectal cancer.与其他癌症相关生物标志物的关联可能导致 RAS 改变的年轻结直肠癌患者预后不良。
Oncologist. 2024 Sep 6;29(9):e1228-e1230. doi: 10.1093/oncolo/oyae153.
2
The histological and molecular characteristics of early-onset colorectal cancer: a systematic review and meta-analysis.早发性结直肠癌的组织学和分子特征:一项系统综述和荟萃分析。
Front Oncol. 2024 Apr 26;14:1349572. doi: 10.3389/fonc.2024.1349572. eCollection 2024.
3
Targeting Myeloid-Derived Suppressor Cell Trafficking as a Novel Immunotherapeutic Approach in Microsatellite Stable Colorectal Cancer.
靶向髓源性抑制细胞的迁移作为微卫星稳定型结直肠癌的一种新型免疫治疗方法
Cancers (Basel). 2023 Nov 20;15(22):5484. doi: 10.3390/cancers15225484.
4
The microbiome and rise of early-onset cancers: knowledge gaps and research opportunities.微生物组与早发性癌症的兴起:知识空白与研究机遇。
Gut Microbes. 2023 Dec;15(2):2269623. doi: 10.1080/19490976.2023.2269623. Epub 2023 Oct 30.
5
Mechanism-Based Redesign of GAP to Activate Oncogenic Ras.基于机制的 GAP 重设计以激活致癌 Ras。
J Am Chem Soc. 2023 Sep 20;145(37):20302-20310. doi: 10.1021/jacs.3c04330. Epub 2023 Sep 8.
6
The Prognostic Value of Total Tumor Volume Response Compared With RECIST1.1 in Patients With Initially Unresectable Colorectal Liver Metastases Undergoing Systemic Treatment.在接受全身治疗的初始不可切除结直肠癌肝转移患者中,与RECIST1.1相比,总肿瘤体积反应的预后价值
Ann Surg Open. 2021 Oct 28;2(4):e103. doi: 10.1097/AS9.0000000000000103. eCollection 2021 Dec.
7
Early Onset Metastatic Colorectal Cancer: Current Insights and Clinical Management of a Rising Condition.早期转移性结直肠癌:对一种日益常见疾病的当前见解与临床管理
Cancers (Basel). 2023 Jul 5;15(13):3509. doi: 10.3390/cancers15133509.
8
Impact of Primary Tumor Location and Genomic Alterations on Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Colorectal Peritoneal Metastases.原发肿瘤位置和基因组改变对结直肠腹膜转移行细胞减灭术和腹腔热灌注化疗后生存的影响。
Ann Surg Oncol. 2023 Jul;30(7):4459-4470. doi: 10.1245/s10434-023-13463-x. Epub 2023 Apr 21.
9
The prognostic significance of clinicopathological characteristics in early-onset versus late-onset colorectal cancer liver metastases.早发性与晚发性结直肠癌肝转移中临床病理特征的预后意义
Int J Colorectal Dis. 2023 Jan 20;38(1):19. doi: 10.1007/s00384-023-04317-9.
10
Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines.德尔菲早期结直肠癌倡议(DIRECT)国际管理指南。
Clin Gastroenterol Hepatol. 2023 Mar;21(3):581-603.e33. doi: 10.1016/j.cgh.2022.12.006. Epub 2022 Dec 20.